Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target mRNAs with partial complementarity to the shRNA-SON guide strand refers to a population of unintended cellular transcripts that are suppressed during RNA interference (RNAi) experiments targeting the SON DNA binding protein. This phenomenon, known as miRNA-like off-targeting, occurs when the guide strand of an shRNA possesses a seed sequence (nucleotides 2-8) that is complementary to the 3' untranslated regions (UTRs) of non-target mRNAs (Jackson et al., 2003, Nature Biotechnology). Because the SON protein is a master regulator of RNA splicing and cell cycle progression, particularly in hematopoietic and leukemic cells, shRNA-mediated knockdown is a common research tool; however, the resulting off-target effects can confound experimental data by inducing phenotypes unrelated to SON depletion (Ahn et al., 2011, Molecular Cell). These off-target interactions are a major concern in the development of RNAi-based therapeutics, as they can lead to unintended toxicity and reduced therapeutic index (Birmingham et al., 2006, Nature Methods). Consequently, identifying and mitigating these interactions through advanced computational design and transcriptomic validation is essential for ensuring the specificity of gene-silencing interventions. In the specific case of shRNA-SON, these off-targets represent any cellular mRNA possessing sequences complementary to the SON-specific guide strand's seed sequence, potentially leading to widespread and unpredictable changes in the cellular proteome.
Unintended gene silencing via RISC-mediated mRNA degradation or translational inhibition driven by partial sequence complementarity, typically involving the seed region of the guide strand.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target mRNAs with partial complementarity to shRNA-SON guide strand.